Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 208(3): 301-315, 2022 06 23.
Artigo em Inglês | MEDLINE | ID: mdl-35404420

RESUMO

Vδ2+ T cells can recognize malignantly transformed cells as well as those infected with mycobacteria. This cross-reactivity supports the idea of using mycobacteria to manipulate Vδ2+ T cells in cancer immunotherapy. To date, therapeutic interventions using Vδ2+ T cells in cancer have involved expanding these cells in or ex vivo using zoledronic acid (ZA). Here, we show that the mycobacterium Bacillus Calmette-Guérin (BCG) also causes Vδ2+ T-cell expansion in vitro and that resulting Vδ2+ cell populations are cytotoxic toward tumour cell lines. We show that both ZA and BCG-expanded Vδ2+ cells effectively killed both Daudi and THP-1 cells. THP-1 cell killing by both ZA and BCG-expanded Vδ2+ cells was enhanced by treatment of targets cells with ZA. Although no difference in cytotoxic activity between ZA- and BCG-expanded Vδ2+ cells was observed, BCG-expanded cells degranulated more and produced a more diverse range of cytokines upon tumour cell recognition compared to ZA-expanded cells. ZA-expanded Vδ2+ cells were shown to upregulate exhaustion marker CD57 to a greater extent than BCG-expanded Vδ2+ cells. Furthermore, ZA expansion was associated with upregulation of inhibitory markers PD-1 and TIM3 in a dose-dependent manner whereas PD-1 expression was not increased following expansion using BCG. Intradermal BCG vaccination of rhesus macaques caused in vivo expansion of Vδ2+ cells. In combination with the aforementioned in vitro data, this finding suggests that BCG treatment could induce expansion of Vδ2+ T cells with enhanced anti-tumour potential compared to ZA treatment and that either ZA or BCG could be used intratumourally as a means to potentiate stronger anti-tumour Vδ2+ T-cell responses.


Assuntos
Mycobacterium bovis , Linfócitos T , Animais , Vacina BCG , Ativação Linfocitária , Macaca mulatta/metabolismo , Receptor de Morte Celular Programada 1 , Receptores de Antígenos de Linfócitos T gama-delta/metabolismo , Ácido Zoledrônico/farmacologia
2.
J Exp Med ; 192(12): 1841-8, 2000 Dec 18.
Artigo em Inglês | MEDLINE | ID: mdl-11120780

RESUMO

Lymphocytes usually differentiate into effector cells within days after antigen exposure, except in germinal centers where terminal differentiation is delayed while somatic hypermutation creates high-affinity antibody mutants. Here we investigate whether arrest of terminal differentiation can be mediated by BCL-6, a transcriptional repressor that is expressed by germinal center B cells and is required for this phase of B cell development. We find that BCL-6 suppresses the differentiation of transformed and primary B cells to plasma cells by inhibiting the signal transducer and activator of transcription 3-dependent expression of the major regulator of plasma cell development, the B lymphocyte-induced maturation protein (Blimp-1). This function of BCL-6 as a repressor of B lymphocyte differentiation may also underlie the association between chromosomal translocations of its gene and B cell lymphomas.


Assuntos
Linfócitos B/citologia , Diferenciação Celular , Proteínas de Ligação a DNA/antagonistas & inibidores , Proteínas de Ligação a DNA/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Transativadores/antagonistas & inibidores , Fatores de Transcrição/metabolismo , Animais , Linfócitos B/efeitos dos fármacos , Linfócitos B/metabolismo , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Citocinas/farmacologia , Proteínas de Ligação a DNA/genética , Citometria de Fluxo , Camundongos , Plasmócitos/citologia , Plasmócitos/efeitos dos fármacos , Plasmócitos/metabolismo , Fator 1 de Ligação ao Domínio I Regulador Positivo , Proteínas Proto-Oncogênicas/genética , Proteínas Proto-Oncogênicas c-bcl-6 , Proteínas Repressoras/metabolismo , Fator de Transcrição STAT3 , Transativadores/metabolismo , Fatores de Transcrição/antagonistas & inibidores , Fatores de Transcrição/genética
3.
Tuberculosis (Edinb) ; 85(1-2): 81-8, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15687031

RESUMO

SETTING: Dendritic cells (DC) could regulate between the protective and pathogenic immune responses following tuberculous infection. In this paper we investigated if their early infection in the lungs represents a plausible alternative to cross-priming with mycobacterial antigens acquired from infected macrophages. OBJECTIVE: To determine the extent and time course of infection of lung DCs following intranasal inoculation of BALB/c mice with green fluorescent protein (GFP) tagged Bacillus Calmette-Guerin (BCG). RESULTS: A fraction of GFP-BCG infected lung cells were classified as monocytic DCs with the CD11c+IA+33D1+CD8a- phenotype. These cells represented 5-18% of the total GFP+ cells, the bulk of which were macrophages. The infected DCs could be separated by cell size into two fractions with similar cell surface staining properties during the 2-72 h period after infection. An unexpected difference was observed for the time course of infection between DCs and macrophages: DC infection peaked at 48 h followed by decline at 72 h, while the proportion of infected macrophages remained steady during the same period. CONCLUSION: The presented results are direct evidence that monocytic DCs are recruited to the lungs and take up live bacilli within 48 h of intranasal infection with GFP-BCG. This finding is pertinent for the regulation of pulmonary and systemic immune responses and possibly for the dissemination of mycobacterial infection by DCs.


Assuntos
Células Dendríticas/imunologia , Pulmão/microbiologia , Infecções por Mycobacterium/imunologia , Administração Intranasal , Animais , Antígenos de Bactérias/imunologia , Antígenos CD/imunologia , Antígenos de Superfície/imunologia , Vacina BCG/administração & dosagem , Tamanho Celular , Proteínas de Fluorescência Verde , Substâncias Luminescentes , Pulmão/patologia , Macrófagos/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Monócitos/imunologia , Infecções por Mycobacterium/patologia , Fatores de Tempo , Tuberculose Pulmonar/imunologia , Tuberculose Pulmonar/patologia
4.
Clin Exp Immunol ; 143(3): 467-73, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16487246

RESUMO

Intranasal inoculation of mice with monoclonal IgA against the alpha-crystallin (acr1) antigen can diminish the tuberculous infection in the lungs. As this effect has been observed only over a short-term, we investigated if it could be extended by inoculation of IFNgamma 3 days before infection, and further co-inoculations with IgA, at 2 h before and 2 and 7 days after aerosol infection with Mycobacterium tuberculosis H37Rv. This treatment reduced the lung infection at 4 weeks more than either IgA or IFNgamma alone (i.e. 17-fold, from 4.2 x 10(7) to 2.5 x 10(6) CFU, P = 0.006), accompanied also by lower granulomatous infiltration of the lungs. IFNgamma added prior to infection of mouse peritoneal macrophages with IgA-opsonized bacilli resulted in a synergistic increase of nitric oxide and TNFalpha production and a 2-3 fold decrease in bacterial counts. Our improved results suggest, that combined treatment with IFNgamma and IgA could be developed towards prophylactic treatment of AIDS patients, or as an adjunct to chemotherapy.


Assuntos
Imunização Passiva/métodos , Imunoglobulina A/uso terapêutico , Interferon gama/uso terapêutico , Tuberculose Pulmonar/prevenção & controle , Administração Intranasal , Animais , Anticorpos Monoclonais/uso terapêutico , Antígenos de Bactérias/imunologia , Células Cultivadas , Contagem de Colônia Microbiana , Quimioterapia Combinada , Feminino , Exposição por Inalação , Macrófagos Alveolares/imunologia , Macrófagos Alveolares/microbiologia , Camundongos , Camundongos Endogâmicos BALB C , Tuberculose Pulmonar/patologia , alfa-Cristalinas/imunologia
5.
Eur J Immunol ; 27(2): 572-5, 1997 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-9045933

RESUMO

Co-ligation of antigen receptor and complement receptor 2 (CD21) in the B cell membrane is important in the immune response to T-dependent antigens. Four CD21 ligands have so far been identified, but only the activated products of the third component of complement (C3) are known to augment the immune response to specific antigens. The most recently discovered ligand for CD21 is CD23. We have generated a CD32+ CD23+ fibroblast cell line which presents a surrogate antigen (anti-IgM) to human tonsil B cells in vitro. Incubation with these cells causes a 10- to 100-fold reduction in the threshold concentration of anti-IgM required for B cell proliferation. Anti-CD19 further enhances the response to antigen and induces proliferation in the absence of anti-IgM. Addition of soluble CD21 totally inhibits the effect of CD23, suggesting that CD21 mediates synergistic signaling by CD23.


Assuntos
Linfócitos B/imunologia , Imunidade/imunologia , Receptores de IgE/análise , Receptores de IgE/imunologia , Anticorpos Anti-Idiotípicos/imunologia , Células Cultivadas , Criança , Pré-Escolar , Humanos , Imunoglobulina M/imunologia , Tonsila Palatina/citologia
6.
Clin Chem ; 38(4): 522-5, 1992 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-1314719

RESUMO

We describe a colorimetric assay for glucose determination in human serum, with use of the chromogen 2-amino-4-hydroxybenzenesulfonic acid (AHBS), glucose oxidase, and peroxidase. With this assay, glucose concentrations less than or equal to 27.8 mmol/L can be measured in serum, with a sample/reagent volume ratio as low as 0.0025. The chromogen itself is easily soluble in water and does not require other components for the color change, making the reagent composition less complex. A single working reagent is used, and the reaction is completed within 10 min at 37 degrees C. The absorbance of the yellow reaction product is measured at 415 nm, and a blank sample measurement is not needed. The average analytical recovery of glucose in different human sera was 97.6%, with no significant interference of reducing compounds in serum. The results of the recommended procedure correlated well with those of the phenol/4-aminoantipyrine method of Trinder.


Assuntos
Glicemia/análise , Colorimetria/métodos , Ácidos Sulfanílicos , Compostos Cromogênicos , Colorimetria/estatística & dados numéricos , Glucose Oxidase , Humanos , Indicadores e Reagentes , Peroxidase , Controle de Qualidade , Espectrofotometria
7.
Glycoconj J ; 9(1): 39-44, 1992 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-1392564

RESUMO

The gene PHO5 coding for one of the repressible acid phosphatases of the yeast Saccharomyces cerevisiae has been expressed at high efficiency in the baby hamster kidney (BHK) cell line. The expression vector was constructed from PHO5 driven by the human beta-actin promoter and was transfected into BHK cells by the calcium phosphate method. The recombinant APase (r-APase) which was secreted in active form from the cells was estimated by SDS/polyacrylamide gel electrophoresis to have molecular mass M(r) = 62,000, indicating substitution of the polypeptide moiety by 2-3 asparagine-linked glycans. Analysis by sequential lectin affinity chromatography of glycopeptides obtained from r-APase with Pronase showed that the glycans are predominantly of the 2.2.4 triantennary and tetraantennary complex-type. These data suggest that the extensive glycosylation of yeast APase, which contains eight polymannose substituents, is not essential for secretion and expression of enzymatic activity of the transfected gene product.


Assuntos
Fosfatase Ácida/fisiologia , Saccharomyces cerevisiae/enzimologia , Fosfatase Ácida/biossíntese , Fosfatase Ácida/metabolismo , Animais , Sequência de Bases , Linhagem Celular , Cricetinae , Eletroforese em Gel de Poliacrilamida , Vetores Genéticos/genética , Glicopeptídeos/análise , Glicosilação , Dados de Sequência Molecular , Transformação Genética/genética
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa